Cancer Communications

Cancer Communications

癌症通讯

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Cancer Communications》是由Wiley出版社于2018年创办的英文国际期刊(ISSN: 2523-3548,E-ISSN: 2523-3548),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为Biochemistry, Genetics and Molecular Biology-Cancer Research。作为SCI、SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA开放获取模式(OA占比1%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比73.47%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在49篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Cancer Communications审稿周期约为4 Weeks。该刊近年未被列入国际预警名单,年发文量约49篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 49 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
2区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2021年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 11 / 333

96.8

学科:ONCOLOGY SCIE Q1 14 / 333

95.95

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 14 / 322

95.8

学科:ONCOLOGY SCIE Q1 16 / 322

95.19

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:40.3 SJR:7.986 SNIP:4.894
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 9 / 428

98%

大类:Medicine 小类:Cancer Research Q1 7 / 233

97%

期刊发文

  • Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Stud

    Author: Li, Haifeng; Chen, Meiting; Huang, Riqing; Rong, Qixiang; Hao, Jing; Zheng, Qiufan; Su, Yanhong; Shu, Ditian; Zhang, Yue; Yang, Wei; Lei, Xuefen; Cai, Yuchen; Xue, Cong; An, Xin; Shi, Yanxia

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0025

  • First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expressio

    Author: Jia, Ru; Wang, Yan-Rong; Liu, Fang-Fang; Ma, Yue; Si, Hai-Yan; Han, Lu; Gou, Miao-Miao; Tan, Zhao-Li; Zhang, Nan; Deng, Guo-Chao; Fan, Meng-Jiao; Shi, Yue; Zhang, Yao-Yue; Jia, Yu-Shan; Xu, Jun-Nan; Su, Xiao-Xing; Han, Quan-Li; Wang, Zhi-Kuan; Dai, Guang-Hai

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0024

  • Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherap

    Author: An, Mengchao; Yan, Jiayao; Liu, Baorui; Liu, Qin

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0023

  • The Roles of Protein S-Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potentia

    Author: Zheng, Haonan; Sun, Xiaoyu; Gao, Yang; Wang, Qinbiao; Wang, Jiaqi; Wei, Minjie; Tang, Yu; He, Miao

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0017

  • TOPK Suppresses the CD8+ T Cell Antitumor Immunity via Modulation of IRF5 Expressio

    Author: Zang, Nianke; Gan, Jinfeng; Chen, Ye; Huang, Zheng; Xie, Chichu; Dang, Junlong; Huang, Changyuan; Yang, Linjie; Chen, Xuelian; Rong, Guangli; Sun, Jianbo; Shao, Yiming; Wang, Julie; Qi, Guangying; Liu, Yu; Zheng, Song Guo

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0021

  • Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Tria

    Author: Bao, Zhaoshi; Xue, Yake; Liu, Yanhui; Li, Shouwei; Wang, Liang; Qu, Yan; Mou, Yonggao; Yu, Rutong; Wu, Jinsong; Yao, Yu; Shu, Kai; Hu, Guangyuan; Cai, Linbo; Li, Wenbin; Qiu, Xiaoguang; Li, Yunqian; Zhang, Lei; Qi, Songtao; Ji, Ying; Ma, Chunxiao; Ma, Wenbin; Li, Gang; Tao, Rongjie; Sun, Chongran; Chen, Ligang; Lv, Sheng-Qing; Liang, Peng; Pan, Hao; Peter, Woo Yat Ming; Danny, Chan Tat Ming; Mao, Qing; Wei, Xinting; Jiang, Tao

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0019

  • Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinom

    Author: Liao, Han; Zhao, Xuan; Chen, Liping; Liu, Qingyi; Li, Chenying; Li, Kai; Xi, Yiyi; Shen, Yanrong; Tan, Wen; Wu, Chen; Lin, Dongxin

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0014

  • WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinom

    Author: Zhu, Can; Wu, Ke; Wu, Tong; Ma, Jun; Ding, Bo; Jiang, Nan; Du, Keyi; Ju, Guomin; Xie, Haiyang; Peng, Chuanhui; Wu, Jian; Zheng, Shusen

    Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0005